Ductal Carcinoma In Situ Close to the Inked Margin: A Case Presented in Multidisciplinary Session With Clinical Discussion and Decision Making
Archives of Breast Cancer · 01.06.2018
DOI: 10.19187/abc.20185258-62 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Breast Cancer, erschienen am 01.06.2018. Verfasst von Ahmad Elahi und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background: For many years, the acceptable margins of the resections for ductal carcinoma in situ (DCIS) has been 2 mm, although, in some reports and the recent updates of some guidelines, the closer margins are also declared as acceptable in some circumstances. Despite these new recommendations, the safe margin in DCIS remains a matter of controversy in many institutional and national guidelines. Case Presentation: A woman with invasive breast cancer with associated DCIS presented to our clinic. She underwent breast-conserving surgery, and pathology report showed one focus of DCIS at a distance of
Schlagwörter
Zitieren
APA
Elahi, A., Toogeh, G., Mahmoodzadeh, H., Jahanbin, B., Shahi, F., Kalaghchi, B., & Sedighi, N. (2018). Ductal Carcinoma In Situ Close to the Inked Margin: A Case Presented in Multidisciplinary Session With Clinical Discussion and Decision Making. Archives of Breast Cancer. https://doi.org/10.19187/abc.20185258-62
Vancouver
Elahi A, Toogeh G, Mahmoodzadeh H, Jahanbin B, Shahi F, Kalaghchi B, et al. Ductal Carcinoma In Situ Close to the Inked Margin: A Case Presented in Multidisciplinary Session With Clinical Discussion and Decision Making. Archives of Breast Cancer. 2018. doi:10.19187/abc.20185258-62
BibTeX
@article{Elahi2018,
author = {Elahi, Ahmad and Toogeh, Gholamreza and Mahmoodzadeh, Habibollah and Jahanbin, Behnaz and Shahi, Farhad and Kalaghchi, Bita and Sedighi, Nahid},
title = {Ductal Carcinoma In Situ Close to the Inked Margin: A Case Presented in Multidisciplinary Session With Clinical Discussion and Decision Making},
journal = {Archives of Breast Cancer},
year = {2018},
doi = {10.19187/abc.20185258-62}
}
EUVIMED